Boston Scientific (BSX) PT Raised at Truist; 'Strong Qtr w/Multiple Tailwinds'

Truist Securities analyst Richard Newitter raised the price target on Boston Scientific (NYSE: BSX) to $125.00 (from $120.00) while maintaining a Buy rating.

The analyst commented: "Strong Qtr w/Multiple Tailwinds Supporting Higher Estimates; Once again, our 2025 ests increase on a beat and raise, and BSX remains a preferred lgcap name for us. PFA upside and accelerating Watchman growth were the standouts but it was a broad based beat. The 2Q beat + ongoing momentum and lower tariff outlook should more than offset TAVR headwind. We believe the company can still deliver upside to now higher guidance and continue to anticipate beat & raises in 2H25. Our 2026 EPS est. increases slightly behind operational increases and a lower tax rate and PT goes to $125 (vs. $120)."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Boeing lands two U.S. defense contracts worth over $711M